CBCD Calls the Participants of HPV2014 Conference to Study Microcompetition
Industry: Health & Fitness
The CBCD believes the HPV conference overemphasizes vaccination, and seems to ignore the millions of already infected individuals.
New York (PRUnderground) August 26th, 2014
The Fred Hutchinson Cancer Research Center reports that there are currently 1,300 scientists, researchers, doctors, and healthcare providers taking part in the HPV2014 conference. The conference is currently underway at the Washington State Convention Center in Seattle. (1) The main focus of the conference is on the prevention of HPV infection through vaccination. “There’s now an incredibly effective vaccine that can prevent high-risk HPV infections from ever developing into cancer… it’s a sexy subject, especially for the media.” (1)
The Center for the Biology of Chronic Disease (CBCD) welcomes the growing interest in the HPV virus. However, the CBCD is concerned that the conference almost completely ignores the millions of people who are already infected with the HPV virus. The overemphasis on prevention marginalizes the significance that the research and development community should place on those who are already infected. After all, existing vaccines do nothing to protect these individuals.
In an existing HPV infection, there are two phases in the lifecycle of the virus. There is the active phase, and the latent phase. Most of the time, the virus is latent in the host. From time to time, the virus reactivates and creates symptoms including genital warts and precancerous changes to cells. Even when participants spend time discussing the infected individuals, they exclusively discuss the active phase. This is because most scientists and physicians believe that latent viruses cause no diseases or symptoms. The FDA even states on its website: “Some viruses, however, can enter a state known as latency in which the virus is not being replicated. In the latent state the virus does not cause disease.” (2) As a result, current standard medical practices don’t target latent viruses.
However, in contrast to this belief, the Microcompetition with Foreign DNA theory, proposed by Hanan Polansky in 2003 (more than 10 years ago), describes how viruses, during their latent phase, including HPV, can cause a chronic disease. (3)
Click to learn more about Microcompetition, by reading Dr. Polansky’s book.
The CBCD believes it is important to remember that most vaccines designed to target active viruses do help save lives by preventing HPV infection. To target latent viruses however, the Center recommends Novirin or Gene-Eden-VIR.
The formula of these natural products is based on Dr. Hanan Polansky’s discovery.
“Even if only a portion of the author’s thesis is correct, it would establish wholly new insights into the pathogenesis of chronic disease states, and would have significant implications for treatment and/or prevention.” – Kim E. Barrett, PhD – Professor of Medicine and Vice-Chair for Research, Department of Medicine, University of California, San Diego.
Click to learn more about Microcompetition with Foreign DNA.
The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the Center for the Biology of Chronic Disease (CBCD) in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (4) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (4)
Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.
The CBCD points out that treatment for individuals who are already infected with HPV is limited to local procedures. In other words, they do not target the HPV virus throughout the body. The virus stays in the body, and can cause symptoms again.
“Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (4) In contrast, Novirin and Gene-Eden-VIR were designed to help people who are already infected with HPV by helping their immune system target the virus while in its latent phase. Additionally, these natural products were shown to reduce HPV symptoms in two separate post-marketing clinical studies.
The CBCD therefore recommends that HPV infected individuals take Novirin or Gene-Eden-VIR.
Interested doctors and scientists can view the two published studies on the formula of Novirin and Gene-Eden-VIR here, http://cbcd.net/Gene-Eden-VIR-Clinical-Study.php and http://cbcd.net/Gene-Eden-VIR-Decreases-Fatigue-Clinical-Study.php.
(1) Fred Hutchinson Cancer Research Center – Finding better ways to treat, prevent HPV. Published August 22, 2014.
(2) FDA – Long-Term Follow-Up Of Gene Transfer Patients. Published October 24, 2001.
(4) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published September 2013.
The Center for the Biology of Chronic Disease (http://www.cbcd.net) is a not-for-profit tax-exempt organization under section 501(c) 3 of the IRS tax code. The center’s mission is to advance the research on the biology of chronic disease and to accelerate the discovery of a cure for these diseases. The CBCD first published Dr. Hanan Polansky’s highly acclaimed “Purple” book, entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” in 2003. In this book, he explains how foreign DNA fragments can cause many major diseases. The book has been read by more than 5,000 scientists around the world, and has been reviewed in more than 20 leading scientific journals. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.